Immutep Limited
NASDAQ:IMMPBiotechnology
+$0.00 today
- Market cap
- $55.01M
- Beta
- 2.24
- P/E (TTM)
- -0.9
- EPS (TTM)
- -$0.06
Volume 3.10M
Average 13.46M
IMMP Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Immutep LimitedNASDAQ: IMMP
Stock-Based Compensation · Q2 FY2026 · quarter ended Dec 2025
Stock-based compensation outflow grows to A$0
Q2 FY2026 stock-based compensation was A$0, compared with A$0 a year earlier. Over 3 fiscal years it compounded at -7.8% a year.
Context
- Stock-based compensation amounted to 23.1% of revenue in FY2025, down 23.7 pp from a year earlier.
- Stock-based compensation increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
AUD · from the cash flow
- Latest · FY2025
- 1.16M AUD
- Year-over-year change
- -35.2%
- 4-year CAGR
- -9.1%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-06-30 | 1.16M | -35.2% |
| FY2024 | 2024-06-30 | 1.8M | -10.3% |
| FY2023 | 2023-06-30 | 2M | +34.6% |
| FY2022 | 2022-06-30 | 1.49M | -12.6% |
| FY2021 | 2021-06-30 | 1.7M | — |
Stock-Based Compensation vs competitors
How IMMP compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -35.2% is the 10th highest of 11, against a peer median of -7.9%.
- Stock-based compensation amounts to 23.1% of revenue for IMMP, versus a peer median of 23.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $3.98B USD | +32410.1% | +56.9% | — | |
| LTM Mar 2026 | $33.74M USD | -35.1% | -23.4% | — | |
| LTM Mar 2026 | $21.03M USD | +1.0% | +44.8% | — | |
| LTM Mar 2026 | $19.27M USD | -0.0% | +25.6% | 335.8% | |
| LTM Mar 2026 | $9.12M USD | -45.7% | -30.1% | 23.6% | |
| LTM Mar 2026 | $9.07M USD | -23.3% | -16.5% | 4.2% | |
| LTM Mar 2026 | $6.93M USD | -9.1% | +16.8% | 1385.0% | |
| LTM Mar 2026 | $5.84M USD | -6.8% | +38.9% | — | |
| LTM Mar 2026 | $4.96M USD | +8.1% | +18.3% | — | |
| LTM Mar 2026 | €2.03M EUR | -21.0% | — | 15.1% | |
| FY2025 | A$1.16M AUD | -35.2% | -7.8% | 23.1% | |
| Peer median (excluding IMMP) | — | -7.9% | +18.3% | 23.6% | |
Competitors are the stored peer set for IMMP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Jun 2021 | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 |
|---|---|---|---|---|---|
| Net Income | (29.9M) | (32.21M) | (39.9M) | (42.72M) | (61.43M) |
| Depreciation & Amortization | 2.07M | 2.06M | 2.06M | 2.26M | 2.39M |
| Deferred Income Tax | (7.29M) | 0 | (4.99M) | 0 | 0 |
| Stock-Based Compensation | 1.7M | 1.49M | 2M | 1.8M | 1.16M |
| Change in Working Capital | (1.99M) | (1.56M) | 764.6K | 3.46M | (8.54M) |
| Accounts Receivables | (2.83M) | (2.25M) | (1.61M) | 601.77K | (2.52M) |
| Inventory | 0 | 813.92K | 0 | 0 | 0 |
| Accounts Payables | 1.38M | 1.44M | 3.27M | 0 | 0 |
| Other Working Capital | (543.42K) | (1.56M) | (900.11K) | 2.86M | (6.02M) |
| Other Non-Cash Items | 17.77M | (8.04K) | 4.17M | 379.87K | 4.37M |
| Operating Cash Flow | (17.64M) | (30.23M) | (35.88M) | (34.82M) | (62.05M) |
| Capital Expenditures | (15.6K) | (22.91K) | (47K) | (932.37K) | (45.77K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | (20.09M) | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 16K | (903.15K) | (38.49M) |
| Investing Cash Flow | (15.6K) | (22.91K) | (31K) | (21.02M) | (38.53M) |
| Debt Repayment | (214.38K) | (222.54K) | (211.97K) | (226.49K) | (270.67K) |
| Common Stock Issued | 43.31M | 52.98M | 80.08M | 100.24M | (164.79K) |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 9.59M | (2.43M) | (3.83M) | (4.83M) | (254.46K) |
| Financing Cash Flow | 52.68M | 50.33M | 76.04M | 95.18M | (525.12K) |
| Effect of Forex Changes | (752.84K) | (671.04K) | 3.3M | (967.73K) | 6.73M |
| Net Change in Cash | 34.27M | 19.4M | 43.42M | 38.37M | (94.38M) |
| Free Cash Flow | (17.66M) | (30.25M) | (35.93M) | (35.75M) | (62.1M) |
Immutep Limited
NASDAQ:IMMP
Intrinsic Alpha fair value
Locked
Current Price
$0.37
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.